Compare GE Aerospace (GE) vs Mesoblast Limited (MESO) Price & Performance

GE AerospaceTrade

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

GE Aerospace vs Mesoblast Limited — how do they compare? GE Aerospace trades at $349.1 (market cap $375.97B), while Mesoblast Limited trades at $19.22 (market cap $2.31B). The key difference: GE Aerospace is far larger — about 162.8× Mesoblast Limited's market cap, and GE Aerospace pays a 0.52% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

	GE	MESO
Market Cap	$375.97B	$2.31B
Sector	Industrials	Technology
52-Week High	$378.68	$20.96
52-Week Low	$259.00	$11.35
Enterprise Value	$385.26B	$2.32B
Dividend Yield	0.52%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Aerospace

GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.

Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.

Mesoblast Limited

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GE Aerospace expects strong Q2 2026 with EPS $1.86 and 16.8% revenue growth, stock target raised to $400.Rayan Ahmad · 17 hours agoBullish Mar Vista's U.S. Quality strategy gains 12.71% in Q2 2026, lagging broader market indexes.Seeking Alpha · 2 days agoBullish GE Aerospace stock rises nearly 17% YTD but lags behind broader industrial ETF's 18% gain.24/7 Wall Street · 3 days agoBullish View details →

MESO

Mesoblast completes treatment of 300 patients in Phase 3 trial for chronic low back pain therapy.GlobeNewsWire · 2 days agoBullish View details →

About GE Aerospace

General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.